中國汽研(601965.SH):控股股東正與中國檢驗認證集團開展檢驗檢測業務整合事宜
格隆匯5月13日丨中國汽研(601965.SH)公佈,中國通用技術(集團)控股有限責任公司(“通用技術集團”)是公司的控股股東。
2022年5月13日,公司接到通用技術集團通知:通用技術集團正在與中國檢驗認證(集團)有限公司開展檢驗檢測業務整合事宜,此次整合或將導致公司控股股東發生變更,但不會導致實際控制人發生變更。有關方案尚未確定,方案確定後需要獲得有關主管部門批准。此次整合不會對公司正常生產經營活動構成重大影響。
此次整合事項,尚處於籌劃階段,有關事項具有不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.